Analyst: More pressing issues for Veloxis
The Danish biotech company Veloxis should have dealt with its funding situation before making changes to its executive board, says Danske Bank analyst Thomas Bowers.
BY STEFAN SINGH KAILAY
The Danish biotech company Veloxis announced immediate changes to its group management late last week. Current CEO Bill Polvino is leaving and will be replaced by fellow American Craig A. Collard. Danske Bank’s healthcare analyst, Thomas Bowers, is not impressed with the timing and would have liked to see another crucial issue dealt with prior to the managerial changes.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Veloxis parts ways with CEO
For abonnenter
Veloxis launches transplant drug in the US
For abonnenter
